Jacobs Levy Equity Management’s BioAge Labs BIOA Stock Holding History

Jacobs Levy Equity Management’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.24M	Sell	377,085 -43,038	-10%	-$778K	0.03%	326
2026 Q1	$7.35M	Buy	420,123 +85,997	+26%	+$1.66M	0.03%	351
2025 Q4	$4.42M	Buy	334,126 +121,038	+57%	+$1.07M	0.02%	432
2025 Q3	$1.25M	Sell	213,088 -60,364	-22%	-$283K	0.01%	672
2025 Q2	$1.13M	Buy	+273,452	New	+$1.1M	﹤0.01%	735

Other funds holding BIOA

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Jacobs Levy Equity Management's BIOA Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its BioAge Labs (BIOA) stake by 10% in Q2 2026, selling an estimated $778K and leaving 377,085 shares worth $9.24M. The position accounts for 0.03% of the portfolio, ranked #326.

Jacobs Levy Equity Management first reported a position in BIOA in Q2 2025 and has held it in 5 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

Jacobs Levy Equity Management held 377,085 shares of BioAge Labs worth $9.24M as of Q2 2026.
Jacobs Levy Equity Management sold 43,038 BioAge Labs shares in Q2 2026, an estimated $778K.
BioAge Labs made up 0.03% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #326 holding.
Jacobs Levy Equity Management first reported a position in BioAge Labs in Q2 2025 and has held it in 5 quarters since.
150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.